Every material Form 8-K Baxter International filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Baxter issued $2.0 billion of senior notes in three series due 2029, 2030 and 2035, receiving about $1.99 billion in net proceeds, and used part of the proceeds to repay its term loan credit agreement in full on December 4, 2025. The company also announced early results and pricing for cash tender offers for certain 2026 and 2027 notes, with a $600 million cap on the purchases.
Notes issued: $300 million 4.450% due 2029, $700 million 4.900% due 2030 and $1.0 billion 5.650% due 2035
Net proceeds of about $1.99 billion, before estimated offering expenses
Term loan credit agreement repaid in full on December 4, 2025
2027 notes tender offer subject to a $600 million cap and a proration factor of about 56%; $614,370,000 principal to be accepted on the Early Settlement Date of December 8, 2025
Baxter International entered into Amendment No. 1 on November 25, 2025, to its amended and restated five-year credit agreement dated June 11, 2025. The amendment raises the maximum net leverage ratio the company must meet for the four fiscal quarters ending December 31, 2025 through September 30, 2026. The filing does not state the new ratio levels, and the change sets a looser borrowing limit for that period.
Amendment No. 1 is dated November 25, 2025, and amends the credit agreement dated June 11, 2025.
The maximum net leverage ratio is increased for the quarters ending December 31, 2025, March 30, 2026, June 30, 2026, and September 30, 2026.
JPMorgan Chase Bank, N.A. is administrative agent; the full text is filed as Exhibit 10.1.
Baxter International said Executive Vice President and Group President, Pharmaceuticals Alok Sonig notified the company on November 5, 2025, that he will resign effective December 1, 2025, to join a company in the healthcare industry. The filing does not name a successor or describe the reasons beyond the new role, so shareholders will need later disclosures to judge how the departure affects the pharmaceuticals business.
Alok Sonig gave notice of resignation on November 5, 2025.
His resignation as Executive Vice President and Group President, Pharmaceuticals takes effect December 1, 2025.
He is leaving to join a company in the healthcare industry; the filing does not name that company.
Baxter reported third-quarter 2025 sales from continuing operations of $2.84 billion, up 5% on a reported basis, and adjusted diluted EPS of $0.69, up 41% from a year earlier. U.S. GAAP results were a loss, driven by $172 million of income tax expense, and the company set full-year 2025 adjusted EPS guidance of $2.35 to $2.40 while Andrew Hider joined as president and CEO.
Q3 sales from continuing operations were $2.84 billion, up 5% reported and 2% operational; U.S. sales declined 1% operationally
U.S. GAAP net loss from continuing operations was $51 million, or $0.10 per diluted share, including $172 million of income tax expense
Full-year 2025 adjusted EPS guidance is $2.35 to $2.40; fourth-quarter guidance is $0.52 to $0.57
Baxter International said Executive Vice President and Chief Operating Officer Heather Knight will resign effective October 29, 2025, to join a healthcare company, and she also leaves her interim role leading Medical Products and Therapies. CEO Andrew Hider will take over that interim group president role, and the company will have no COO after the transition date. The filing gives no financial figures, but the loss of a COO and the added duties for the CEO are leadership changes shareholders may want to watch.
Heather Knight resigns as EVP and COO, effective October 29, 2025, to join a healthcare industry company
Knight also steps down as interim group president of Medical Products and Therapies on the same date
CEO Andrew Hider will assume the interim MPT group president role
After October 29, 2025, Baxter will no longer have a chief operating officer
Baxter reported second-quarter 2025 sales from continuing operations of $2.81 billion, up 4% on a reported basis and 1% on an operational basis, which the company said was in line with its prior guidance. Adjusted diluted EPS from continuing operations rose 28% to $0.59, while U.S. GAAP diluted EPS from continuing operations was $0.24. The company also updated its full-year 2025 adjusted EPS guidance to $2.42 to $2.52.
Q2 2025 sales from continuing operations of $2.81 billion, up 4% reported and 1% operational
Adjusted diluted EPS from continuing operations of $0.59, up 28% from the prior year; GAAP diluted EPS from continuing operations of $0.24
Full-year 2025 adjusted EPS from continuing operations guidance of $2.42 to $2.52; third-quarter guidance of $0.58 to $0.62
Andrew Hider's appointment as president and CEO was previously announced July 7, 2025, with a start date by Sept. 3, 2025
Baxter International appointed Andrew Hider, CEO of ATS Corporation since 2017, as president and chief executive officer and a director, effective on the earlier of September 3, 2025 or a date the company and Hider agree, subject to his existing contractual obligations. Brent Shafer, interim CEO and chair since February 2025, will move to non-executive chair and rejoin two board committees as an independent director. The filing discloses Hider's pay package, including a $1,350,000 base salary, a 150% target bonus and a $14,000,000 annual long-term incentive target value.
Hider's effective date is the earlier of September 3, 2025 or a date agreed with Baxter, subject to his current employer obligations
Base salary of $1,350,000 with a target annual bonus of 150% of salary and a $14,000,000 LTI target value
One-time sign-on package includes a $1,000,000 cash payment and a $4,000,000 supplemental equity award, plus a $5,750,000 RSU and $2,750,000 PSU make-whole award
Board size increases to eleven directors to accommodate Hider's appointment
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Baxter International filing is on SEC EDGAR ↗. 8-K briefs of other companies →